BioDelivery Sciences International Inc. (NASDAQ:BDSI) has earned a consensus rating of “Hold” from the seven ratings firms that are presently covering the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $6.33.

Several equities analysts recently weighed in on the stock. Janney Montgomery Scott restated a “hold” rating and set a $4.00 target price on shares of BioDelivery Sciences International in a report on Tuesday, July 12th. Zacks Investment Research upgraded shares of BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a report on Thursday, July 14th. Cantor Fitzgerald restated a “hold” rating on shares of BioDelivery Sciences International in a report on Saturday, July 9th. Piper Jaffray Cos. restated a “sell” rating and set a $4.00 target price on shares of BioDelivery Sciences International in a report on Wednesday, August 10th. Finally, FBR & Co restated a “buy” rating on shares of BioDelivery Sciences International in a report on Tuesday, September 20th.

BioDelivery Sciences International (NASDAQ:BDSI) opened at 2.35 on Thursday. The firm has a 50-day moving average of $2.50 and a 200 day moving average of $2.63. The firm’s market cap is $126.05 million. BioDelivery Sciences International has a 1-year low of $1.86 and a 1-year high of $7.00.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.31). The company had revenue of $5 million for the quarter, compared to analyst estimates of $3.35 million. BioDelivery Sciences International had a negative net margin of 109.64% and a negative return on equity of 233.80%. BioDelivery Sciences International’s revenue for the quarter was up 194.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.37) EPS. On average, analysts predict that BioDelivery Sciences International will post ($1.14) EPS for the current year.

In related news, Director William B. Stone sold 16,000 shares of BioDelivery Sciences International stock in a transaction on Thursday, August 11th. The shares were sold at an average price of $2.57, for a total transaction of $41,120.00. Following the sale, the director now owns 122,675 shares of the company’s stock, valued at approximately $315,274.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Paolantonio Ernest Robert De sold 14,800 shares of BioDelivery Sciences International stock in a transaction on Thursday, September 22nd. The stock was sold at an average price of $2.44, for a total transaction of $36,112.00. Following the sale, the chief financial officer now directly owns 14,866 shares in the company, valued at approximately $36,273.04. The disclosure for this sale can be found here. Corporate insiders own 9.00% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co. NY increased its stake in BioDelivery Sciences International by 1.8% in the first quarter. Metropolitan Life Insurance Co. NY now owns 32,132 shares of the specialty pharmaceutical company’s stock valued at $104,000 after buying an additional 581 shares during the last quarter. Alpine Partners VI LLC bought a new stake in BioDelivery Sciences International during the second quarter valued at $147,000. Krilogy Financial LLC bought a new stake in BioDelivery Sciences International during the second quarter valued at $164,000. Menta Capital LLC bought a new stake in BioDelivery Sciences International during the second quarter valued at $224,000. Finally, Laurion Capital Management LP bought a new stake in BioDelivery Sciences International during the second quarter valued at $257,000. 60.39% of the stock is currently owned by hedge funds and other institutional investors.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

5 Day Chart for NASDAQ:BDSI

Receive News & Stock Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related stocks with our FREE daily email newsletter.